Literature DB >> 2189784

A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity.

O Schwartz1, J L Virelizier, L Montagnier, U Hazan.   

Abstract

A microtransfection method, using either the DEAE-dextran or the Ca.phosphate procedure has been developed. A plasmid expressing the luciferase-encoding gene under the control of the human immunodeficiency virus (HIV) LTR promoter was constructed. Transfections were performed in 96-well plates, allowing statistical evaluation of the results. This microtransfection method requires the use of 100- to 1000-fold less plasmid and cells than in a conventional chloramphenicol acetyl transferase (CAT) assay. A Luciferase index which takes into account cell viability after transfection has been defined using a semi-automated absorbance assay. A 20-h incubation period post-transfection is sufficient for optimal results. Basal long terminal repeat activity and autologous Tat transactivation were studied in various lymphoid, monocytic and adherent human cell lines. Infection of microtransfected cells by HIV activated luc expression. This assay can thus also be used for rapid detection and quantitation of HIV. Antiviral activities of drugs can be assessed in a two-day test.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189784     DOI: 10.1016/0378-1119(90)90032-m

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  39 in total

1.  High level transient gene expression in human lymphoid cells by SV40 large T antigen boost.

Authors:  R de Chasseval; J P de Villartay
Journal:  Nucleic Acids Res       Date:  1992-01-25       Impact factor: 16.971

2.  Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses.

Authors:  J L Battini; J M Heard; O Danos
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

3.  Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.

Authors:  O Schwartz; V Maréchal; B Friguet; F Arenzana-Seisdedos; J M Heard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Octamer independent activation of transcription from the kappa immunoglobulin germline promoter.

Authors:  A Prabhu; D P O'Brien; G L Weisner; R Fulton; B Van Ness
Journal:  Nucleic Acids Res       Date:  1996-12-01       Impact factor: 16.971

5.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  High-level replication of human immunodeficiency virus in thymocytes requires NF-kappaB activation through interaction with thymic epithelial cells.

Authors:  L Chêne; M T Nugeyre; F Barré-Sinoussi; N Israël
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells.

Authors:  S C Flores; J C Marecki; K P Harper; S K Bose; S K Nelson; J M McCord
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

8.  Modulation of T-cell activation through protein kinase C- or A-dependent signalling pathways synergistically increases human immunodeficiency virus long terminal repeat induction by cytomegalovirus immediate-early proteins.

Authors:  C V Paya; J L Virelizier; S Michelson
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

9.  Investigation of the intracellular stability and formation of a triple helix formed with a short purine oligonucleotide targeted to the murine c-pim-1 proto-oncogene promotor.

Authors:  F Svinarchuk; A Debin; J R Bertrand; C Malvy
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

10.  Induction of galectin-1 expression by HTLV-I Tax and its impact on HTLV-I infectivity.

Authors:  Sonia Gauthier; Isabelle Pelletier; Michel Ouellet; Amandine Vargas; Michel J Tremblay; Sachiko Sato; Benoit Barbeau
Journal:  Retrovirology       Date:  2008-11-25       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.